Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIP-200 Phage Therapy for Chronic E. Faecium PJI
NCT06942624Phase 2Not yet recruiting
- Sponsor
- Orthopaedic Innovation Centre
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CIP-200 in periprosthetic joint infection (PJI), sponsored by Orthopaedic Innovation Centre. Primary endpoints: Safety of phage therapy at 1 year, Efficacy of phage therapy at 1 year and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
CIP-200
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT06942624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942624.